Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus CECLOR CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus CECLOR CD.
ANCEF vs CECLOR CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Renal: ~80% unchanged; biliary/fecal: ~20%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic